Clinical trial
A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
NCT07719543 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Multicenter Randomized Double-Blind Placebo-Controlled Study Evaluating the Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- August 1, 2026
- Completion date
- December 31, 2030
- Enrollment
- 146 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.